GET THE APP
Ashok Srivastava is the Chief Medical Officer of Trans Atlantic Therapeutics Oncology, He was the Chief Medical Officer of CareBeyond - A Radiation Therapy Cancer Center, New Jersey, USA. He has more than 15 years of experience in drug development, medical affairs, and commercialization of cancer drugs including radiopharmaceutical and supportive care; Phase I – 4, and marketing commercialization of Hematology, Oncology, and radiopharmaceutical drugs in the USA, EU, and Japan. He is the leader in Cancer Drug Development Worldwide large and complex Phase 3 Clinical Trials in many countries. He contributed to 21-INDs and 7-NDAs of Cancer Drugs, the acquisition /merger of a company and drug for more than $300 million. He received his clinical, and medical training & worked at renowned medical centers and pharmaceutical institutions worldwide; Walter Reed Army Institute of Research and Medical Center, Daiichi, Sumitomo, Pharmacia, Pfizer, Eisai Oncology, and Spectrum Pharmaceuticals. He received his Clinical, Medical & Business educations from All India Institute of Medical Sciences, New Delhi, India; the Academy of Medical Sciences, Czechoslovakia; the School of Medicine Nagasaki University, Japan, and Pharmaceutical Business at Rutgers University Business Management, New Jersey, USA. He played a key role in a dramatic expansion of oncology drug–developed cancer drugs- Sutent (Sunitinib), Evoxac (Cevimeline HCl), and liposomal doxorubicin (Myocet) in combination with Herceptin & Paclitaxel for HER2 positive metastatic breast cancer patients and latuda (Lurasidone) for schizophrenia He is one of the inventors of Japanese encephalitis vaccine (IXIARO). He has published more than 85 papers in National and International Journals, more than 120 abstracts, 3 book chapters, and 2 patents. He is the recipient of numerous National & International prestigious medical awards and recognitions from the United Nations, Ministry of Health, Japan, Department of Army, Walter Reed Army Medical Center, and Walter Reed Army Institute of Research, Washington DC, USA. He served as a medical advisor to Poniard Pharmaceutical for small-cell lung cancer in the USA, EU, and India. Srivastava is a member of numerous prestigious organizations; America’s Top Oncologist of the years 2007, 2008, and 2011, Breast Cancer Foundation, Indian Society of Oncology, American Society of Clinical Oncology, American Society for Therapeutic Radiology & Oncology, American Association of Cancer Research, and International Society of Lung Cancer. Dr. Srivastava is a strategic medical advisor and Board Member to several pharma in the USA for clinical, regulatory, and supervises cancer drug development. Recently Dr. Srivastava was awarded membership in Japan External Trade Organization, USA. Dr. Srivastava is a Leader in Drug Safety, pharmacovigilance of Oncology, hematology, and immuno-oncology and built global drug safety and pharmacovigilance companies in the USA, and India. Dr. Srivastava was invited as an honorable speaker at the drug safety & Pharmacovigilance congress in London, UK, China, India, and Washington, DC, USA in Jan 2012, 2013, and 2017. Dr. Srivastava brought 2 cancer drugs & a vaccine to a global market for approx 3 – 3.5 billion $ in global sales. He serves on the board of directors for oncology virtual pharma companies in the USA. He is on the Board of advisors to Calidi Biotherapeutics.
Professor Ahmed Hashash has completed his PhD from Manchester University, UK. He is a fellow of
the California Institute of Regenerative Medicine (CIRM) and New York University Medical School
(MSSM), USA. Prof. Ahmed Hashash worked as a senior biomedical research scientist at Mount
Sinai School of Medicine of New York University and Children’s Hospital Los Angeles. He was
Assistant Professor and Principal Investigator of Stem Cell & Regenerative Medicine at Keck School
of Medicine and Ostrow School of Dentistry of The University of Southern California, USA. In 2016,
Prof. Hashash has joined The University of Edinburgh, Edinburgh Medical School-Zhejiang
International Campus, (ZJU) as Tenure-Track Associate Professor and Senior Principal Investigator
of Biomedicine, Stem Cell & Regenerative Medicine. He is also adjunct Professor at the School of
Basic Medical Science and School of Medicine, Zhejiang University.